Food and Drug Administration
Center for Drug Evaluation and Research

Oncologic Drugs Advisory Committee

73rd Meeting

Holiday Inn
8170 Wisconsin Avenue
Bethesda, Maryland

Agenda — December 17-18, 2002

12:30	Call to Order and Opening Remarks	Donna Przepiorka, M.D., Ph.D. Chair, ODAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Executive Secretary, ODAC
12:45	Open Public Hearing	

BL STN 125011/0, Bexxar®, Tositumomab (Anti-B1) and Iodine^{131}-Tositumomab
Corixa Corporation

- indicated for the treatment of patients with relapsed or refractory low-grade, follicular or transformed low-grade, B-cell non-Hodgkin's lymphoma (NHL) including patients with rituximab refractory follicular non-Hodgkin's lymphoma

1:15	**Sponsor Presentation**	**Corixa Corporation**
2:15	Break	
2:30	**FDA Presentation**	
3:30	Questions from the Committee	
4:30	Committee Discussion and Vote	
5:30	Estimated Time of Adjournment	

December 18, 2002

8:00	Call to Order and Opening Remarks	Donna Przepiorka, M.D., Ph.D. Chair, ODAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Executive Secretary, ODAC
8:15	Open Public Hearing	

NDA 20-498, S012, CASODEX® (150 mg bicalutamide), AstraZeneca Pharmaceuticals LP

- indicated as (1) adjuvant therapy to radical prostatectomy and radiotherapy of curative intent in patients with locally advanced non-metastatic prostate cancer who have a high risk for disease recurrence or (2) immediate treatment of localized non-metastatic prostate cancer in patients for whom therapy of curative intent is not indicated

8:45	**Sponsor Presentation**	**AstraZeneca Pharmaceuticals LP**
9:45	Break	
10:00	**FDA Presentation**	
11:00	Questions from the Committee	
12:00	Lunch	
1:00	Committee Discussion and Vote	
3:00	Estimated Time of Adjournment	